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NSCLCAim: Improve the prognostic prediction of clinical variables for non-small cell lung cancer (NSCLC), by
selecting from blood-biomarkers, non-invasively describing hypoxia, inflammation and tumour load.
Methods: Model development and validation included 182 and 181 inoperable stage I-IIIB NSCLC patients
treated radically with radiotherapy (55.2%) or chemo-radiotherapy (44.8%). Least absolute shrinkage and
selection operator (LASSO), selected from blood-biomarkers related to hypoxia [osteopontin (OPN) and
carbonic anhydrase IX (CA-IX)], inflammation [interleukin-6 (IL-6), IL-8, and C-reactive protein (CRP)],
and tumour load [carcinoembryonic antigen (CEA), and cytokeratin fragment 21-1 (Cyfra 21-1)].
Sequent model extension selected from alpha-2-macroglobulin (a2M), serum interleukin-2 receptor
(sIL2r), toll-like receptor 4 (TLR4), and vascular endothelial growth factor (VEGF). Discrimination was
reported by concordance-index.
Results: OPN and Cyfra 21-1 (hazard ratios of 3.3 and 1.7) significantly improved a clinical model
comprising gender, World Health Organization performance-status, forced expiratory volume in 1 s,
number of positive lymph node stations, and gross tumour volume, from a concordance-index of 0.66
to 0.70 (validation = 0.62 and 0.66). Extension of the validated model yielded a concordance-index of
0.67, including a2M, sIL2r and VEGF (hazard ratios of 4.6, 3.1, and 1.4).
Conclusion: Improvement of a clinical model including hypoxia and tumour load blood-biomarkers was
validated. New immunological markers were associated with overall survival. Data and models can be
found at www.cancerdata.org (http://dx.doi.org/10.17195/candat.2016.04.1) and www.predictcancer.org.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 487–494
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nd/4.0/).In the last three decades, lung cancer has been the leading cause
of cancer deaths [1]. To increase the survival of lung cancer
patients, we have witnessed an improvement of radiotherapy tech-
niques and more effective (chemo)radiotherapy schemes (i.e.,
introduction of concurrent treatment) [2–4]. Attempts have been
made to develop more accurate risk stratification for non-small cell
lung cancer (NSCLC) patients, which would lead to more tailored,
individualized and personalized care, avoiding over or
under-treatment, by means of a radiation oncology based onmultifactorial Decision Support Systems [5,6]. Therefore, the inves-
tigation of new prognostic parameters derived from, but not lim-
ited to, anatomic, molecular and functional imaging, genomics,
and proteomics is warranted [7–9].
The analysis of biomarkers, including proteins, is a fast-
developing, promising and challenging area of research, permitting
the prediction or description of the evolution of normal biological
processes, pathogenic processes, or pharmacological responses to
a therapeutic intervention [10]. Oncoproteins are produced by
tumour cells or in response to their presence, and may be released
into the bloodstream of cancer patients. As tissue sampling is often
not possible in lung cancer patients, blood sample collection by
venipuncture is an attractive alternative, which is safe and easy to
implement [10]. Blood-biomarkers reflect dissimilarities of the
tumour microenvironment, are linked to disease prognosis and
488 Prognostic value of blood-biomarkers in NSCLCresponse to treatment. Blood-biomarkers, that can be measured in
daily clinical practice and have been shown to be associated with
treatment outcome were first identified in studies comprising large
datasets. Based on this criterion, those which biological functions
are related to processes of hypoxia [osteopontin (OPN) and carbonic
anhydrase IX (CA-IX)]; inflammation [interleukin 6 (IL-6), IL-8, and
C-reactive protein (CRP)], and tumour load [carcinoembryonic anti-
gen (CEA) and cytokeratin fragment (CYFRA 21-1)], were analysed
and externally validated [11–25]. As an exploratory step we inves-
tigated additional blood-biomarkers, including those related to
immunological response, which could therefore be incorporated
into immunotherapy assessment studies: alpha-2-macroglobulin
(a2M), serum IL-2 receptor (sIL2R), toll-like receptor 4 (TLR4),
and vascular endothelial growth factor (VEGF) [14,26–35].Patients and methods
Development dataset
The development cohort included 195 stage I-IIIb NSCLC
patients treated with (chemo)radiotherapy between October
2003 and October 2008. Clinical data and blood samples were
prospectively collected to ensure standardization. Exclusion crite-
ria included surgery or palliative treatment, and insufficient mate-
rial to perform blood measurements (OPN, CA-IX, IL-6, IL-8, CRP,
CEA, and CYFRA 21-1). All patients participated in the Biobank pro-
ject (Clinical trials.gov identifiers: NCT00181519, NCT00573040,
and NCT00572325) launched in 2003, and provided written
informed consent. One hundred and eighty-two patients were
treated according to dissimilar radiotherapy (RT) regimens, with
a minimum dose of 50 Gy:
1. Forty-nine patients (26.8%) received the standard external
beam radiation therapy (EBRT) protocol used until August
2005, of either 70 Gy (Stage I–II) or 60 Gy after induction
chemotherapy (Stage III) in once-daily fractions of 2 Gy.
2. One hundred and one patients (55.2%) were treated with EBRT
only according to the protocol as of August 2005, with an
individualized dose delivered in fractions of 1.8 Gy twice daily,
until normal tissue dose constraints were met (e.g., mean lung
dose, or maximum dose to the spinal cord) [36].
3. Thirty-three patients (18%) received concurrent (chemo)radio-
therapy with a total dose of 45 Gy, delivered in fractions of
1.5 Gy twice daily, followed by an individualized dose of 8 to
24 Gy delivered in fractions of 2.0 Gy once daily, again limited
by the dose to surrounding organs at risk [37].
Validation dataset
The validation cohort consisted of 200 NSCLC patients with
same characteristics as the development cohort, treated between
March 2007 and September 2013. Measurements included the
above mentioned blood-biomarkers plus VEGF, a2 M, TLR4 and
sIL2R (Clinicaltrials.gov identifier: NCT01936571). One hundred
and eighty-one patients received a minimum dose of 50 Gy and
were treated as follows:
1. Sixty-eight patients (37.6%) received radiotherapy alone
according to the protocol as of August 2005, with an individual-
ized total dose delivered in fractions of 1.8 Gy twice daily, lim-
ited by the mean lung dose or the spinal cord dose [36].
2. One hundred and one patients (55.8%) received concurrent
chemo-radiotherapy scheme for a prescribed dose of 45 Gy,
followed by an individualized dose ranging from 8 to 24 Gy,
delivered in fractions of 2.0 Gy once daily, again limited by
the dose to surrounding organs at risk [37].3. Twelve patients (6.6%) followed the Phase II Positron Emission
Tomography (PET) boost trial (clinicaltrals.gov identifier
NCT01024829), in which a dose escalation protocol was based
on the Fluorine-18-Fluorodeoxyglucose distribution of the PET
scans [38].
Radiation treatment
Patients were irradiated in accordance with local protocols and
stage of the disease. No elective nodal irradiation was performed
and irradiation was delivered 5 days a week [39]. Radiotherapy
planning was performed on a XiO system (Computerised Medical
Systems) until July 2012, using a convolution–superposition
algorithm with inhomogeneity corrections and according to Inter-
national Commission on Radiation Units & Measurements 50
guidelines. As of July 2012, radiotherapy planning was performed
using RapidArc (Eclipse version 11.0), with a type B dose calcula-
tion algorithm (AcurosXB-10.0).Endpoint
Study endpoint was overall survival (OS) calculated from start
of RT until the date of death or last follow-up. Survival information
was retrieved from ‘‘Gemeentelijke Basis Administratie” (GBA), the
decentralized population registration system in the Netherlands. A
patient who was alive at the end of the study was considered right-
censored.Blood-biomarker measurement
Blood-biomarkers measurements of the development dataset
can be found elsewhere [40]. Measurements of the validation
cohort were performed in a certified laboratory, using commer-
cially available kits, in order to easily translate the results into clin-
ical practice. For each patient, 3 aliquots of 0.5 ml of serum and 3
aliquots of 1.5 ml of plasma were available, which had been col-
lected before the first fraction of radiotherapy, processed using
standard protocols and finally stored in the institutional biobank.
Measurements in plasma were performed using enzyme-linked
immunosorbent assays for OPN (Quantikine Human Osteopontin
Immuno assay; R&D Systems, Minneapolis, MN), CA-IX (Nuclea
Diagnostics, Cambridge, MA), VEGF (R&D Systems), and TLR4
(MyBioSource, San Diego, CA). Measurements in serum for IL-6
and IL-8 were determined on Immulite XPi 2000 with a solid
phase, enzyme labelled, chemoluminescence sequential immuno-
metric assay (Siemens Medical Solutions Diagnostics, LA), for CRP
on Cobas 8000 using an immunoturbimetric assay (Roche Diagnos-
tics, Mannheim, Germany), for CEA on Immulite XPi using a solid-
phase, two-site sequential chemoluminescent immunometric
assay (Siemens Medical Solutions Diagnostics), for CYFRA 21-1
on Kryptor with a sandwich immuno-fluorescent assay (Brahms,
ThermoFisher, Hennigsdorf, Germany), for a2M on BN ProSpec
using immunonephelometric assays (Siemens Medical Solutions
Diagnostics, LA, USA), and for sIL2R using an enzyme-linked
immunosorbent assay (Diaclone, Basancon Cedex, France).
The analytes OPN, CA-IX, VEGF and TLR4 were assayed in
plasma in duplicate using a Victor multilabel counter (Perkinelmer,
Turku, Finland), while all other biomarkers were measured in
singletons.Descriptive statistics
Comparison of the development and validation datasets distri-
butions was performed using a v2 test for categorical variables
and a Student t-test for the continuous ones. Prior to this a variable
transformation on the gross tumour volume (GTV) and blood
S. Carvalho et al. / Radiotherapy and Oncology 119 (2016) 487–494 489biomarker measurements were performed, using a logarithmic
approach. Missing data imputation was performed by Multivariate
Imputation by Chained Equations (MICE). Correlation analysis was
performed between clinical and blood-biomarker variables under
analysis for both datasets.Model development
A Cox proportional hazards model was developed and included
validated clinical variables: gender, World Health Organization
performance status (WHO-PS), forced expiratory volume in one
second (FEV1s), number of positive lymph node stations identified
in the diagnostic PET scans (lymph nodes) and GTV, defined as the
sum of the GTV of the primary tumour and metastatic lymph nodes
[41]. A least absolute shrinkage and selection operator (LASSO)
method was applied for feature selection of the blood-
biomarkers, entered as continuous variables into the model. LASSO
selects variables correlated to the measured outcome by shrinking
coefficients weights, down to zero for the ones not correlated to
outcome [42]. Regression coefficients were estimated, using the
whole dataset, hazard ratios (HR) and confidence intervals (CI)
were calculated. Schoenfeld residuals were used to check the pro-
portional hazards assumption. Discrimination, reflecting a correct
ordering of the relative predictions with respect to true outcomes
(i.e. overall survival) for individuals, and model’s ability to distin-
guish between individuals who experience the outcome from those
who remained event free, was determined by the Harrell’s
concordance-index (c-index). This ranges from 0.5, no discrimina-
tion (no greater than the chance expectation) to 1 indicating per-
fect discrimination.External model validation
Calibration of the model, which refers to the agreement
between observed and predicted probabilities, was visually
assessed (further details in the appendix). Discrimination ability
of the model was also determined by the Harrell’s c-index in an
independent dataset.Fig. 1. Kaplan–Meier plots for overall survivalModel updating
The prognostic index (PI) was computed by multiplying the
covariates with the estimated coefficients on the validation data-
set: PI ¼Pibixi. The validated model was extended by inputting
the PI (recalibrated if necessary) as a fixed variable and further
selecting among new proposed blood-biomarkers. Performance
was evaluated by means of an internal 10-fold CV c-index (further
details in the appendix). A log likelihood test of model fit was con-
ducted between the validated and extended model.
All statistical methods were performed in R (version 2.15.2),
using the libraries survcomp, survival, rms, glmnet and corrplot [43].Results
Upon analysis, 161 and 132 patients in the derivation and vali-
dation cohorts, respectively, had died, and median follow-up time
was 8.2 (95% CI: 7.3–9.3) and 3.6 years (95% CI: 3.2–4.6). Kaplan
Meier plots of the overall survival for both datasets are shown in
Fig. 1. Patient characteristics and blood biomarker measurements
are shown in Tables 1 and 2, including the missing measurements
count. Homogeneity tests on the blood-biomarkers measures
reflect the small differences that could be observed between
development and validation datasets, for which a non-significant
p-value could be demonstrated. The exception to this lies on IL-8,
that was significantly higher in the validation dataset, with, how-
ever, a non-drastically higher median. The highest Pearson correla-
tion was 0.61 between IL-6 and CRP in the development dataset
(r = 0.72 in the validation dataset). Correlation between clinical
features and blood-biomarkers was lower than 0.5 for all compar-
isons, demonstrating that these variables provide Complementary
information (Fig. 2). Radiotherapy administered doses Radiother-
apy regimen up to August 2005 had an HR = 0.17 (p < 0.01), while
the one afterwards had an HR = 0.90 (p = 0.52). Concurrent scheme
presented with an HR = 0.62 (p = 0.03). Administered dose had a
risk of 0.98 (p = 0.03).
The model including solely clinical parameters achieved a per-
formance with a c-index of 0.66 (p < 0.01). The automatic featurefor development and validation datasets.
Table 1
Demographic information of the study population. Comparison between datasets
distribution were performed after missing data imputation, with a v2 test for
categorical variables and a Student t-test for the continuous ones (*).
Derivation
dataset
(n = 182)
Validation
dataset
(n = 181)
p-Value*
Age 0.40
Range (median) 42–87 (69) 44–88 (68)
Mean ± SD 67.2 ± 10.5 68 ± 9.3
Gender 0.09
Male 139 (76.4%) 123 (68%)
Female 43 (23.6%) 58 (32%)
Stage 0.06
I 33 (18.1%) 20 (11%)
II 14 (7.7%) 25 (13.8%)
IIIa 48 (26.4%) 49 (27.1%)
IIIb 87 (47.8%) 85 (47%)
Unknown (M0) 2 (1.1%)
Histology <0.01
Adenocarcinoma 26 (14.3%) 39 (21.5%)
Squamous cell 49 (26.9%) 68 (37.6%)
NOS 91 (50%) 66 (36.5%)
Unknown 16 (8.8%) 8 (4.4%)
WHO-PS 0.43
0 47 (25.8%) 48 (26.5%)
1 81 (44.5%) 93 (51.4%)
P2 17 (9.3%) 28 (15.5%)
Unknown 37 12 (6.6%)
FEV 1s 0.90
Range (median) 33–124 (76) 25–136 (76)
Mean ± SD 74 ± 23.3 74 ± 24
Unknown 14
Lymph nodes 0.02
0 73 (40.1%) 45 (24.9%)
1 26 (14.3%) 28 (15.5%)
2 32 (17.6%) 34 (18.8%)
3 20 (11%) 25 (13.8%)
P4 31 (17%) 49 (27%)
GTV (cm3) 0.12
Range (median) 0.84–674.4 (63.5) 6.15–1076 (104)
Mean ± SD 89.8 ± 97.7 128 ± 142
Unknown 3 8
Radiotherapy (Range (mean ± SD), in Gy)
Standard protocol
Before August
2005
58–70 (62.4 ± 4.3) –
After August
2005
50.40–79.2
(64.2 ± 9.8)
52.2–79.2
(68.9 ± 11.9)
<0.01
Concurrent
scheme
First Dose 45–51 (46.9 ± 3.5) 45 (45.9 ± 6.1)
Second Dose 8–24 Gy
(13.3 ± 8.8)
8–24 (22.0 ± 7.2)
PET Boost – 46.8 – 95.5
(71.9 ± 11.7)
Acronyms: SD – Standard Deviation; NOS – not otherwise specified, also includes
patients categorized as ‘‘large cell”; WHO-PS – world health organization perfor-
mance status; FEV 1 s – forced expiratory volume in 1 s; Lymph nodes refer to the
PET positive stations identified; GTV – gross tumour volume (GTV = volume of
primary tumour + volume of PET positive lymph node stations).
* Significance of the homogeneity tests between datasets distributions.
490 Prognostic value of blood-biomarkers in NSCLCselection algorithm used (LASSO), selected from the blood-
biomarkers and extended the clinical model with OPN and Cyfra
21-1 (hazard ratios (HR) of 3.3 and 1.7), which led to a significant
improvement in the performance up to 0.70 (p < 0.01; Table 3).
Starting point for automatic feature selection methodology
includes simultaneous consideration of all 8 biomarkers together
with previously developed clinical model. Then, lower priority is
assigned to features less associated with outcome, and therefore
removed from the final model. Finally, features associated withsurvival outcome and not mutually correlated, were retained for
the final model.
As a side remark, most of the analysed blood biomarkers
presented with a univariable significance correlation to overall sur-
vival (results in the online appendix), with the exception of CA-IX
and IL-8. In addition, features included in final model presented
with the most prominent HR of 7.2 (OPN) and 2.38 (Cyfra 21-1).
External validation of the clinical model yielded a c-index of
0.62 while the extended one improved to 0.66. Despite the lower
performance of the external validation, the addition of blood-
biomarkers again showed an improvement in the performance. A
nomogram based on this model is presented in the online appendix
of this manuscript.
In an exploratory exercise, the validated model was extended
with a2M, sIL2r, and VEGF, and presented a c-index of 0.67
(p < 0.01; 10-fold CV c-index = 0.66, Table 4). The validated model,
as in Table 3, is represented by its prognostic index (PI) in a new
automatic feature selection routine, that extends it to include the
mentioned blood-biomarkers. Adding these biomarkers resulted
in a better fitted model (p = 0.01; likelihood ratio test), and partic-
ularly a2M and sIL2r were significantly associated with survival
with HR of 4.6 and 3.1. Further details on how this extension is per-
formed are descripted in the appendix, including model’s
recalibration.Discussion
Prognostic modelling of NSCLC is becoming an important ele-
ment of the disease management. Several sources of information
now available make it an emerging and constantly changing field,
however the choice for non-invasive techniques is preferred in
order to diminish the burden for patients. The use of blood-
biomarker measurements appears to be a non-invasive, fast and
promising source of extra information, reflecting dissimilarities
of the tumour microenvironment that has been shown to be asso-
ciated with disease prognosis and response to treatment [44,45].
We demonstrated and validated in two large cohorts of NSCLC
patients the added value of blood-biomarkers related to hypoxia
(OPN) and tumour load (Cyfra 21-1), reflected by a statistically sig-
nificant improvement in the performance of a clinical model after
their inclusion. A priori selection of blood-biomarkers was based on
a literature search and evidence of their prognostic value for NSCLC
[11–25]. Hypoxia affects malignant progression by increasing the
tumour’s metastatic ability and diminishing the apoptotic poten-
tial, and also the response to therapy, by decreasing the effects of
anticancer therapies including (chemo)radiotherapy [44]. In addi-
tion, imaging studies with hypoxia-specific markers have shown
that hypoxia is a prevalent effect in NSCLC [46]. The hypoxia mar-
ker OPN, has also been associated with tumour aggressiveness and
metastatic potential, accompanying a poor prognosis in NSCLC,
confirmed rather strongly in our study (HR = 3.3) [19,20]. Tumour
load is often associated with disease development and prognosis
[41,47]. Cyfra 21-1, a marker associated with tumour load, was
previously identified as a prognostic factor for NSCLC, which was
also confirmed in our analysis [48].
We have already investigated the prognostic potential of
blood-biomarkers using a support vector machine (SVM) for model
development. We then extended a validated 2-year survival clini-
cal model with blood-biomarkers related to inflammation (IL-6)
and tumour load (CEA). Performance expressed as the area under
the curve (AUC) improved from 0.72 (solely clinical parameters)
to 0.81 [40,41]. However, the limited number of patients included
in the study made it difficult to draw definitive conclusions. More-
over, SVM is less suited to a time-to-event analysis, as it requires
dichotomous outcome. Therefore we re-analysed the data,
Table 2
Distribution of the blood-biomarkers after data imputation: range (median); mean ± standard deviation. Biomarkers were not measured in case there was not enough material.
New biomarkers were available in the latest measurements solely performed in the validation dataset. Comparison of blood-biomarkers distribution in the two datasets was
conducted with a Student t-test (*).
Blood biomarker Development dataset
(n = 182)
Range (median)
Mean ± SD
Not measured Validation dataset
(n = 181)
Range (median)
Mean ± SD
Not measured p-Value*
Hypoxia
Osteopontin (OPN) 40–304 (99)
111 ± 46
3 16–1802 (140)
128 ± 137
1 0.13
Carbonic Anhydrase IX (CA-IX) 59–2477 (221)
337 ± 346
2 48–8508 (254)
402 ± 696
1 0.26
Inflammation
Interleukin 6 (IL-6) 1.1–86 (7.2)
10 ± 11
4 1.8–462 (6.4)
14 ± 39
0 0.26
Interleukin 8 (IL-8) 2.3–91 (11)
14 ± 13
5 4.7–316 (13)
20 ± 28
0 0.01
C-reactive protein (CRP) 1–315 (12)
26 ± 41
16 0.9–258 (8.8)
24 ± 39
0 0.55
Tumour load
Carcinoembryonic antigen (CEA) 0.8–1806 (4.3)
32 ± 152
9 0.7–1068 (5.4)
33 ± 115
0 0.91
Cytokeratin fragment (CYFRA 21-1) 0.2–49 (1.7)
3.7 ± 6.4
5 0.1–119 (2.0)
6.2 ± 16
1 0.05
New biomarkers
Alpha-2-Macroglobulin (a2M) 1.1–5.2 (2.3)
2.4 ± 0.8
5
Serum IL-2 receptor (sIL2R) 1121–20000 (5926)
6129 ± 2907
0
Toll-like receptor 4 (TLR4) 1.4–30 (6.4)
7.5 ± 4.6
1
Vascular Endothelial Growth Factor (VEGF) 18–505 (84)
112 ± 94
1
Acronyms: SD – Standard Deviation.
* Significance of the homogeneity tests between datasets distributions.
Fig. 2. Heat maps illustrating Pearson correlation between clinical features and blood biomarkers in the derivation (left) and validation (right) datasets.
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ately good performance (0.66, external = 0.62) could be achieved
with female gender which is associated with a better prognosis,
given the lower risk (HR = 0.50), while WHO-PSP 2 (HR = 2.65)
and larger GTV (HR = 1.41) are worse prognostic factors.
The validated model was extended to include a2M, sIL2r, and
VEGF. Despite the comparable c-index (0.67; 10-fold CV = 0.66),most importantly it showed that higher concentrations of these
new markers are associated with a worse prognosis, particularly
a2M and sIL2r with HRs of 4.6 and 3.1. Previous studies showed
a2M as a top candidate for radiation pneumonitis [31]. We further
confirmed its prognostic potential for NSCLC. IL-2 was already
identified as an independent prognostic marker in patients with
advanced NSCLC [49]. Its cell surface receptor, a soluble form of
Table 3
Multivariable Cox PH regression of the clinical variables and of clinical variables and blood-biomarkers fitted on the derivation dataset. Performance of the model expressed in
terms of internal and external validation (*) by Harrell’s c-index.
Feature Hazard ratio p-Value 95% CI HR c-index Hazard ratio p-Value 95% CI HR c-index
Gender 0.66
0.62*
0.70
0.66*Male Reference Reference
Female 0.50 <0.01 0.33–0.75 0.54 <0.01 0.36–0.82
WHO-PS
0 Reference Reference
1 1.30 0.01 0.90–1.88 1.20 0.01 0.82–1.74
P2 2.65 1.57–4.45 2.09 1.22–3.58
FEV 1 s 1.00 0.88 0.99–1.01 1.00 0.45 0.99–1.00
Lymph nodes
0 Reference Reference
1 0.63 0.14 0.37–1.06 0.63 0.14 0.37–1.07
2 1.03 0.63–1.66 1.12 0.69–1.83
3 0.59 0.34–1.05 0.62 0.35–1.09
4 0.91 0.57–1.46 1.10 0.68–1.80
ln(GTV) (cm3) 1.41 <0.01 1.21–1.64 1.28 <0.01 1.09–1.50
OPN 3.31 0.01 1.31–8.38
Cyfra 21-1 1.71 0.01 1.18–2.50
A logarithmic transformation was performed on the blood-biomarkers measurements prior to analysis.
Acronyms: CI – Confidence Interval; HR – Hazard Ratio; WHO-PS – World Health Organization Performance Status; FEV 1 s – forced expiratory volume in 1 s; Lymph nodes
refer to the PET positive stations identified; GTV – gross tumour volume (GTV = volume of primary tumour + volume of PET positive lymph node stations); OPN – Osteo-
pontin; Cyfra 21-1 – cytokeratin fragment 21-1
* External validation.
Table 4
Multivariable Cox PH regression of the clinical variables and blood-biomarkers fitted
on the validation dataset, after a feature selection made by LASSO from newly
analysed blood-biomarkers. Performance of the model is expressed in terms of
internal c-index, corrected for optimism by a 10-fold CV (**).
Feature Hazard ratio p-Value 95% CI HR c-index
Calibrated PI* 2.44 <0.01 1.69–3.51 0.67
0.66**a2M 4.62 <0.01 1.31–16.3
sIL2R 3.15 <0.01 1.08–9.21
VEGF 1.37 0.28 0.78–2.43
A logarithmic transformation was performed on the blood-biomarkers measure-
ments prior to analysis
Acronyms: a2M – alpha-2-macroglobulin; sIL2r – serum interleukin-2 receptor;
VEGF – vascular endothelial growth factor.
* Validated model in Table 3 entered as a variable – the calibrated prognostic
index (PI).
** Internal c-index corrected for optimism by a 10-fold CV.
492 Prognostic value of blood-biomarkers in NSCLCIL-2 receptor (sIL2r) is released into the bloodstream and involved
in the regulation of IL-2. High sIL2r levels were associated with
shorter survival in an advanced stage [50,51]. Elevated levels of
sIL2r may lead to a decreased cellular response to IL-2, reinforcing
the importance of measuring this marker for patients receiving IL-2
immunotherapy [51–53]. VEGF, also included in the final model
with a less expressive HR of 1.4, is a common angiogenesis factor
for a variety of solid tumours, including NSCLC [54]. It has been
shown previously to be an independent prognostic factor, which
was not however confirmed by our data [14].
An advantage of our study is the large number of patients avail-
able, making the derived message a more solid one. Conversely,
this study had some limitations. First, it was impossible to validate
our latest findings using the newer biomarkers as these were only
measured in the validation dataset. This should be thoroughly con-
sidered in the future, by gathering data from external institute(s).
The heterogeneity of our dataset, including more recently treated
patients following concurrent schemes in the validation dataset,
the different types and scheduling of chemotherapy, and the differ-
ent laboratories involved in the biomarkers measurements may
provide us to a better understanding of the derived calibration
slope, which is below 1 [55]. However, the c-index achieved in
the context of a prognostic analysis must not be disregarded,
particularly when compared with the limited capacity of humansto infer better prognosis from the same sources of information
[7]. Also due to its great heterogeneity, it is not possible with this
cohort to assess stage-specific treatment variables. We are how-
ever able to deliver a set of prognostic factors, independent of dis-
similar types of treatment or disease stage, but spanning a larger
cohort of heterogeneous patients. This model could be improved
by including other sources of information, for example imaging
(Radiomics), as the relevant prognostic value of sophisticated
image analysis has been shown, to be investigated in the future
[8,9]. One last point that we would like to emphasize is the
increasing number of PET tracers currently available and the ability
to obtain extra information, in particular relating to hypoxia
(18F-FMISO, 18F-FAZA and 18F-HX4), tumour proliferation
(18F-fluorothymidine), and assessment of epidermal growth factor
receptor (EGFR) [56–58]. The potential use of blood-biomarkers to
predict which imaging tracer is best suited to an individual patient,
would convert prognostic markers into predictive information and
increase the cost effectiveness of imaging procedures, while dimin-
ishing patient burden from extensive diagnostic imaging
procedures.
In conclusion, we improved a clinical model by the inclusion of
blood-biomarkers related to hypoxia and tumour load. This
improvement was validated externally, which reinforces its poten-
tial relevance for shared decision-making. An extended model
demonstrated that higher concentrations of the inflammation mar-
ker a2M and immunological marker sIL2r have strong negative
prognostic value for NSCLC, which requires extra validation. Data
are publicly available at www.cancerdata.org (http://dx.doi.org/
10.17195/candat.2016.04.1) and the developed models can be
found at www.predictcancer.org.
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